A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography

Cancer Science

Volumn 97, Issue 11, 2006, Pages 1274-1278

  Nishi, Rie ^a   Yamauchi, Takahiro ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; CYTARABINE; CYTARABINE TRIPHOSPHATE; DNA; GEMCITABINE; GEMCITABINE TRIPHOSPHATE;

ANION EXCHANGE CHROMATOGRAPHY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND; DNA SYNTHESIS INHIBITION; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SOLUTION; DRUG TRANSPORT; ELUTION; ENVIRONMENTAL TEMPERATURE; FLOW RATE; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LINEAR SYSTEM; PARTICLE SIZE; PH MEASUREMENT; PHOSPHORYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SOLID TUMOR; VALIDATION STUDY;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; DEOXYCYTIDINE; HL-60 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; SENSITIVITY AND SPECIFICITY;

EID: 33748950821     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00323.x     Document Type: Article

References (27)

1. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drug 1995; 6 (Suppl 6): 7-13.
2. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22 (4 Suppl 11): 3-10.
3. Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3675-80.
4. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
5. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine (Gemcitabine). Cancer Invest 1990; 8: 313.
6. Gandhi V, Mineishi S, Huang P et al. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol 1995; 22 (4 Suppl 11): 61-7.
7. Garcia-Carbonero R, Ryan DP, Chabner BA. Cytidine analogs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 3rd edn. Philadelphia: Lippincott-Raven Publishers, 2001; 281-5.
8. Gatzemeier U. Indications for chemotherapy in stage IV non-small cell lung cancer. Lung Cancer 2001; 33 (Suppl 1): S109-13.
9. Burris HA 3rd. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 2005; 32 (4 Suppl 6): S1-3.
10. Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003; 17: 1967-72.
11. Angiolillo AL, Whitlock J, Chen Z, Krailo M, Reaman G, Children's Oncology Group. Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report. Pediatr Blood Cancer 2006; 46: 193-7.
12. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA, synthesis. Cancer Res 1991; 51: 6110-17.
13. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 1985; 12 (2 Suppl 3): 20-30.
14. Yamauchi T, Ueda T, Nakamura T. A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res 1996; 56: 1800-4.
15. 4-behenoyl-1- β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res 2001; 92: 975-82.
16. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β- d -arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
17. Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3675-80.
18. Yamauchi T, Ueda T. Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 799: 81-6.
19. Fallon HJ, Frei E III, Davidson JD, Trier JS, Burk D. Leukocyte preparations from human blood: Evaluation of their morphologic and metabolic state. J Lab Clin Med 1962; 59: 779-91.
20. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-β- d -arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 1997; 3: 1539-45.
21. Hubeek I, Peters GJ, Broekhuizen AJ, Kaspers GJ. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1513-16.
22. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823-6.
23. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-62.
24. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
25. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-13.
26. Neoptolemos JP, Cunningham D, Friess H et al. Adjuvant therapy in pancreatic cancer: Historical and current perspectives. Ann Oncol 2003; 14: 675-92.
27. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol 2002; 29 (3 Suppl 12): 10-16.